Article

A Re-Analysis of EU’s COVID-19 Vaccine Procurement Strategy in View of the An-Ticipated Cost-effectiveness of Vaccination

2021-11-18

Abstract excerpt

<h4>Aim: </h4> The EU has received criticism for being slow to secure COVID-19 vaccine contracts in 2020 before the approval of the first COVID-19 vaccine. The purpose of this study is to retrospectively analyze the EU’s COVID-19 vaccine procurement strategy. To this end, the study retrospectively determines the minimum vaccine efficacy that made vaccination cost-effective from a societal perspective in Germany be...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a087167a-3ac0-5f2b-899c-1a3cc1cf9ee8
DOI: 10.21203/rs.3.rs-1034892/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Re-Analysis of EU’s COVID-19 Vaccine Procurement Strategy in View of the An-Ticipated Cost-effectiveness of VaccinationDOI 10.21203/rs.3.rs-1034892/v1Read

Cost-effectiveness of routine COVID-19 adult vaccination programmes in EnglandSemantic proximity Read

Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European RegionSemantic proximity Read

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceSemantic proximity Read

The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in CanadaSemantic proximity Read

Exit strategy of COVID-19 crisis and pathways of VaccinationSemantic proximity Read

Vaccination as an Alternative to Non-Drug Interventions to Prevent Local Resurgence of COVID-19Semantic proximity Read

Untangling the changing impact of non-pharmaceutical interventions and vaccination on European Covid-19 trajectoriesSemantic proximity Read

Vaccination and Non-Pharmaceutical Interventions: When can the UK relax about COVID-19?Semantic proximity Read

Adapting French COVID-19 vaccination campaign duration to variant disseminationSemantic proximity Read

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United StatesSemantic proximity Read

The role of NIH funding in vaccine readiness; foundational research and NIH funding underlying candidate SARS-CoV-2 vaccinesSemantic proximity Read

Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 vaccine in the United StatesSemantic proximity Read